首页|地奈德乳膏联合盐酸西替利嗪治疗尿毒症血液透析皮肤瘙痒患者的临床研究

地奈德乳膏联合盐酸西替利嗪治疗尿毒症血液透析皮肤瘙痒患者的临床研究

扫码查看
目的 观察地奈德乳膏联合盐酸西替利嗪对尿毒症血液透析皮肤瘙痒患者的临床疗效和安全性.方法 将尿毒症血液透析皮肤瘙痒患者按随机数表法分为对照组和试验组.对照组患者口服盐酸西替利嗪片治疗,每次10 mg,qd,连续治疗8周.试验组患者在对照组治疗的基础上给予地奈德乳膏外用治疗,每天早、晚各1次,涂抹适量于患者皮肤瘙痒处,连续治疗8周.比较2组患者的临床疗效,对比2组患者的瘙痒症状、睡眠质量,并进行安全性评价.结果 本试验中共脱落36例,最终试验组和对照组分别纳入52例.治疗后,试验组和对照组的总有效率分别为82.69%(43例/52例)和63.46%(33例/52例),在统计学上差异有统计学意义(P<0.05).治疗后,试验组和对照组的视觉模拟评分(VAS)分别为(2.87±1.29)和(3.62±1.76)分,改良Dou氏瘙痒评分(Dou's VAG)分别为(18.24±3.23)和(20.13±4.59)分,匹兹堡睡眠质量指数(PSQI)分别为(9.57±1.72)和(10.34±2.01)分,试验组的上述指标与对照组比较,在统计学上差异均有统计学意义(均P<0.05).试验组发生的药物不良反应有头晕、恶心、呕吐,对照组发生的药物不良反应有头晕、恶心、呕吐.试验组和对照组的总药物不良反应发生率分别为9.62%(5例/52例)和7.69%(4例/52例),在统计学上差异无统计学意义(P>0.05).结论 地奈德乳膏联用盐酸西替利嗪治疗与尿毒症血液透析患者单用盐酸西替利嗪相比,皮肤瘙痒症状的疗效更佳,安全性较好.
Clinical trial on the combination of dinald cream and sertraline hydrochloride for skin itching in hemodialysis patients with uremic blood
Objective To evaluate the clinical efficacy and safety of desonide cream in combination with cetirizine hydrochloride for the treatment of skin itching in patients with uremia undergoing hemodialysis.Methods Patients with skin itching associated with uremia and hemodialysis were divided into control group and treatment group by random number table.The control group received oral cetirizine hydrochloride,10 mg per dose,once daily for 8 weeks.Patients in the treatment group were treated with desonide cream appropriate amout for external use on the basis of the treatment in the control group,once in the morning and once in the evening every day,and smeared on the pruritus of the patient's skin for 8 weeks.The clinical efficacy of the two groups were compared,and the pruritus symptoms,sleep quality and safety evaluation of the two groups were compared.Results During the trial,a total of 36 cases dropped out,with 52 cases ultimately included in the treatment and control groups,respectively.Following treatment,the total effective rates in the treatment and control groups were 82.69%(43 cases/52 cases)and 63.46%(33 cases/52 cases),respectively,showing statistically significant difference(P<0.05).After treatment,the visual analog scale(VAS)scores for the treatment and control groups were(2.87±1.29)and(3.62±1.76)points,respectively;the modified Dou's analogue grading(Dou's VAG)were(18.24±3.23)and(20.13±4.59)points,respectively;the Pittsburgh sleep quality index(PSQI)scores were(9.57±1.72)and(10.34±2.01)points,respectively.Compared with the control group,the above indexes in treatment group were statistically significant(all P<0.05).The adverse drug reactions of the treatment group were dizziness,nausea and vomiting,and the adverse drug reactions of the control group were dizziness,nausea and vomiting.The total incidence of adverse drug reactions in the treatment group and the control group was 9.62%(5 cases/52 cases)and 7.69%(4 cases/52 cases),respectively,and the difference was no statistically significant(P>0.05).Conclusion The combination of desonide cream and cetirizine hydrochloride has better efficacy and safety than cetirizine hydrochloride alone in treating the itching symptoms of uremic hemodialysis patients.

desonide creamcetirizine hydrochloride tableturemic hemodialysisskin itchingsleep qualityerythrocyte immune functioninflammatory factorsmicroRNAs-146a

陈晓霞、谢席胜、占志朋

展开 >

西南医科大学 临床医学院,四川 泸州 646000

遂宁市中心医院肾内科,四川遂宁 629000

地奈德乳膏 盐酸西替利嗪片 尿毒症血液透析 皮肤瘙痒 睡眠质量 红细胞免疫功能 炎症因子 微小RNA-146a

成都中医药大学"杏林学者"学科人才科研提升计划研究专项基金资助项目

YYZX2020088

2024

中国临床药理学杂志
中国药学会

中国临床药理学杂志

CSTPCD北大核心
影响因子:1.91
ISSN:1001-6821
年,卷(期):2024.40(20)